PhoenixBio (6190) Reports Earnings: Net Sales Decrease 35.3% YoY to 258 Million Yen, Operating Loss of 93 Million Yen

PhoenixBio (6190) has released its financial results, reporting net sales of 258 million yen, representing a 35.3% decrease compared to the same period of the previous year. On the profit front, the company posted an operating loss of 93 million yen, an ordinary loss of 89 million yen, and a net loss attributable to owners of the parent of 91 million yen. Earnings per share (EPS) stood at -22.38 yen.

Regarding the financial structure and key indicators, the equity ratio remains solid at 70.1%, demonstrating a high level of financial stability. Interest-bearing debt was recorded at 300 million yen, while retained earnings stood at -1.91 billion yen. In terms of profitability and efficiency metrics, the company reported a Return on Equity (ROE) of 8.74%, a Return on Assets (ROA) of 5.59%, and an EBITDA of 120 million yen. While the latest results reflect a decline in revenue and earnings, market participants will continue to monitor the company's future recovery and financial strategies supported by its robust capital base.